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Abstract
Background: The growing concern about cannabis use, the most commonly used illicit drug worldwide, has led to a
significant increase in the number of human studies using neuroimaging techniques to determine the effect of cannabis on
brain structure and function. We conducted a systematic review to assess the evidence of the impact of chronic cannabis
use on brain structure and function in adults and adolescents.
Methods: Papers published until August 2012 were included from EMBASE, Medline, PubMed and LILACS databases
following a comprehensive search strategy and pre-determined set of criteria for article selection. Only neuroimaging
studies involving chronic cannabis users with a matched control group were considered.
Results: One hundred and forty-two studies were identified, of which 43 met the established criteria. Eight studies were in
adolescent population. Neuroimaging studies provide evidence of morphological brain alterations in both population
groups, particularly in the medial temporal and frontal cortices, as well as the cerebellum. These effects may be related to
the amount of cannabis exposure. Functional neuroimaging studies suggest different patterns of resting global and brain
activity during the performance of several cognitive tasks both in adolescents and adults, which may indicate compensatory
effects in response to chronic cannabis exposure.
Limitations: However, the results pointed out methodological limitations of the work conducted to date and considerable
heterogeneity in the findings.
Conclusion: Chronic cannabis use may alter brain structure and function in adult and adolescent population. Further
studies should consider the use of convergent methodology, prospective large samples involving adolescent to adulthood
subjects, and data-sharing initiatives.
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Translational Medicine (INCT-TM, Conselho Nacional de Desenvolvimiento CientÃ-fico e TecnolÃ2gico (CNPq), Brazil (J.A. Crippa, R. MartÃ-n-Santos); S.
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Introduction
Cannabis is the illicit drug most widely available and used
worldwide [1,2], consumed by between 125 and 203 million
people, largely younger age group (15–34 years), which corre-
sponds to an annual prevalence rate of 2.8%–4.5% [1,2]. Despite
the fact that many individuals tend to discontinue cannabis use
after their initial experimentation with the drug [1] and the
percentage of individuals who develop dependence is lower than
that associated with alcohol (15%) or tobacco (32%) use, around
9% of cannabis users develop dependence in the long term [3,4].
Cannabis use has been associated with a range of acute and
chronic mental health problems, such as anxiety, depression,
neurocognitive alterations and deficits as well as increased risk of
psychotic symptoms and disorders, the severity of these effects
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being dependent on frequency of use, age of onset and genetic
vulnerability [5–15]. These effects are probably related to effects
on the endocannabinoid system, which can modulate the neuronal
activity of other neurotransmitter systems, such as dopamine,
through its action on the most abundant cannabinoid receptor in
brain, the cannabinoid receptor 1 (CB1) [16,17]. CB1 receptors
mature slowly, reaching maximal levels during adolescence [18],
and are particularly concentrated in brain regions that are critical
for executive functioning, reward processing and memory, such as
the prefrontal cortex, anterior cingulate cortex, basal ganglia,
medial temporal areas (e.g., hippocampus and amygdala) and
cerebellum [19].
Animal studies have consistently demonstrated that delta-9-
tetrahydrocannabinol (THC), the main psychoactive component
of cannabis [20], is able to disrupt the regulatory role of the
endogenous cannabinoid system [21], inducing neurotoxic
changes in brain regions rich with cannabinoid receptors that
might dramatically affect the process of maturational refinement of
cortical neuronal networks [22–24] and lastly promote changes in
brain structure and alter emotional and cognitive performance
[25], particularly if the exposure has been during the adolescent
period [26,27]. In contrast to animal literature, results from
human studies investigating chronic cannabis users are often
inconsistent. These discrepancies may be due to heterogeneity in
socio-demographic characteristics of the population studied,
imaging techniques employed, as well as differences in drug usage
patterns and psychiatric comorbidities that may not always be
apparent or result in contact with mental health services and hence
may not be appropriately controlled for in studies where
participants are screened for presence of co-morbid psychiatric
disorder merely by enquiring about previous contact with mental
health services [28–30]. However, overall the results suggest that
long-term cannabis use may result in persistent alterations in brain
function and morphology that would extend beyond the period of
intoxication [28,31], and that earlier onset of use may be
associated with greater detrimental effects [32,33].
It is remarkable to note that although the onset of cannabis use
is typically during adolescence, a few imaging studies have been
conducted with adolescent users [28,34]. Since brain development
continues up to young adulthood [35], adolescence may be a
critical period during which chronic cannabis exposure may have
far-reaching consequences [36]. Although brain size is thought to
stabilize around the age of five years [37], important neurodevel-
opmental processes continue throughout adolescence, including
myelinization [38], synaptic refinement [39] and gray matter
volume reduction [40]. While the long-term effects of cannabis use
may potentially have major implications for social and family life,
education and occupational functioning, its effects on brain
structure and function have not been well determined.
The growing concern about cannabis use has led to a significant
increase in the number of human studies using neuroimaging
techniques to determine the effect of the substance on brain
structure and function, as well as to several recent reviews
examining this topic [28,29,34,41–46]. However, some authors
have only reviewed studies investigating the acute effects of
cannabis [45,46] or those published over the last decade [41,44],
while others did not adequately specify criteria for selecting studies
[41,43] or included those studies that investigated only adult
population [29,42]. In the present review, we have conducted a
systematic literature search to assess and integrate the evidence of
the impact of chronic cannabis use on brain structure and
function, focusing on studies in the adolescent and adult
population. Papers published until August 2012 have been
included following a comprehensive search strategy and pre-
determined set of criteria for article selection [29].
Methods
Data for this systematic review was collected with an advanced
document protocol in accordance with the PRISMA guidelines
[47]. This protocol provided a checklist for reporting systematic
reviews (see Table S1).
Search strategy
Electronic searches were performed using EMBASE (1980-
August 2012), Medline (1966-August 2012), PubMed (1966-
August 2012) and LILACS (1982-August 2012) databases. The
following key words were used: cannabis; marijuana; marihuana;
delta-9-tetrahydrocannabinol; THC; cannabidiol, CBD; neuroim-
aging; brain imaging; computerized tomography, CT; magnetic
resonance, MRI; single photon emission tomography, SPECT;
functional magnetic resonance, fMRI; positron emission tomog-
raphy, PET; diffusion tensor MRI, DTI-MRI; spectroscopy,
MRS. All the studies published up to August 2012 were included
without language restriction.
Selection criteria
A general review of all neuroimaging studies investigating brain
structure or function was initially performed. We obtained a total
of 142 published papers (Figure 1). Studies were included or
excluded if they expressly stated the following criteria. Inclusion
criteria were: (i) use of structural or functional neuroimaging
techniques involving chronic cannabis users; (ii) inclusion of a
control group of healthy volunteers matched by age, gender and
handedness; and (iii) users had to be abstinent for at least 12 hours
before brain scanning. Exclusion criteria were: (i) non-neuroim-
aging studies of cannabis use; (ii) neuroimaging studies that
involved participants who had other neurological or psychiatric
disorders, or individuals who met criteria for alcohol dependence
or other substance use disorders (abuse or dependence) different
from cannabis and nicotine, or participants who were not
abstinent or who tested positive for drugs other than cannabis
on urine screening test; and (iii) neuroimaging studies with
recreational or naı̈ve cannabis users.
We defined chronic cannabis users as persons who used
cannabis several times a week and who had done so for at least
two years. Recreational (or occasional) cannabis users were
defined as persons who had used cannabis sporadically (less than
four times a month), and naı̈ve users or healthy controls were
persons who had used cannabis less than 15 times in their lifetime,
according to standardized strict criteria [29,48].
Any publication that reported data using two different
neuroimaging techniques from the same subjects (e.g., structural
MRI and functional MRI) or a study examining the same subjects
with two different cognitive tasks (e.g., verbal working memory
and visual attention task) was considered as two studies in this
review.
Data extraction
Data was independently extracted by two reviewers. In case of
disagreement, opinion from a third senior researcher was sought to
assess whether study criteria were fulfilled. From the articles
included we recorded names of authors, year of publication, socio-
demographic (e.g., sample size, gender, age, handedness) and
cannabis use characteristics (e.g., duration, age of onset, frequency
of cannabis use), imaging type and design, exclusion criteria (for
neurological, psychiatric or drug history), confirmation of absti-
Neuroimaging Studies in Chronic Cannabis Users
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nence from other drugs (whether checked by urine test), rest/
active condition (for functional imaging studies), type of cognitive
task performed during functional imaging and psychopathological
variables assessed (e.g., psychotic or depressive symptoms). With
regard to alcohol use, we assessed if subjects met criteria for
alcohol abuse or for excessive alcohol consumption (more than 21
or 14 standard alcohol units per week for males or females,
respectively) based on the reported data. For structural and
functional imaging data, the primary measures of interest were
global and regional volume, and global and regional activity
[cerebral blood flow (CBF), regional CBF (rCBF) or blood oxygen
level dependent signal BOLD)]. The secondary outcome was its
correlation with clinical variables. We collected the statistically
significant results of each outcome variable, and recorded whether
a multiple comparison correction was done to prevent bias
towards false positives.
Figure 1. Flow diagram of included neuroimaging studies in chronic cannabis users.
doi:10.1371/journal.pone.0055821.g001
Neuroimaging Studies in Chronic Cannabis Users
PLOS ONE | www.plosone.org 3 February 2013 | Volume 8 | Issue 2 | e55821
Results
Of the 142 studies identified, thirty-six did not meet the a priori
selection criteria [33,49–84] and sixty-two met the exclusion
criteria [6,12,30,48,85–141] or were case/series reports [142] (for
more detailed information, see Figure 1). The remaining 43 studies
were classified according to the neuroimaging technique used
(structural/functional), age of the participants [adolescents (# 18
years) and adults (. 18 years] and testing conditions (resting state/
cognitive task) (Figure 1). The studies included comprised: 14
structural neuroimaging studies [11 in adult users and 3 in
adolescent users; 10 volumetric studies and 4 diffusion tensor
imaging studies (DTI)] and 29 functional neuroimaging studies on
the chronic effects of cannabis (24 in adult users and 5 in
adolescent users; 8 in the resting state and 21 during a cognitive
task).
1. Structural neuroimaging studies in adult chronic
cannabis users
We identified 11 structural MRI studies that examined adult
chronic cannabis users and met our selection criteria (Table 1).
Structural differences were obtained in seven of them in terms of
global brain measures [143] or gray/white matter changes [144–
149]. Four studies did not find any significant structural alterations
when comparing chronic cannabis users with healthy controls
[150–153]. The abstinence period for all participants before they
underwent the structural MRI was between 12 and 24 hours,
apart from two studies [145,152] (for details see Table 1).
1.1. Volumetric studies. Of the seven studies comparing
global brain volume measures between chronic cannabis users and
healthy controls, there was only one study reporting significant
differences [143], namely reduced ventricular cerebral spinal fluid
(CSF) in cannabis users. Another study [145] reported total brain
volume difference between groups which was no longer significant
when the authors covaried for confounding factors such as
premorbid intelligence.
Among the six studies employing a whole-brain analysis
approach [143,146,148,150–152], two further studies described
differences between chronic cannabis users and controls
[146,148]. Matochik et al. (2005) [148] found lower grey matter
density in the right parahippocampus and greater grey matter
density in the precentral gyrus and right thalamus in cannabis
users, while Cousjin et al. (2011) [146] found a larger anterior
cerebellum in cannabis users. Matochik et al. (2005) [148] also
reported differences in white matter density, such as lower density
in the left parietal lobe and higher in parahippocampus, fusiform
gyrus, lentiform nucleus and pons.
With regard to the three studies that focused on specific regions
of interest, all studies reported bilateral volumetric reductions in
the hippocampus [145,148,149] and one reported volume
reductions in the right amygdala [149]. Some studies have also
reported correlations between regional brain volume measures
and cannabis use parameters, clinical and neuropsychological
measures. For instance, a smaller hippocampal volume has been
related to a greater exposure to cannabis [145,146,149], severity of
cannabis dependence [146] and more severe positive psychotic
symptoms [149]. Ashtari et al. (2011) [145] described a positive
association between larger hippocampus volumes and higher
verbal learning and memory scores in healthy controls but not in
cannabis users [145]. It is remarkable to note that these findings
were in patients with an average of 6.7 months of abstinence,
which appears to support of the idea that cannabis use may cause
long-term brain alterations.
With respect to other brain regions, Cousijn et al. (2011) [146]
reported a negative correlation between amygdala volume and the
amount of cannabis use or dependence, while Matochik et al.
(2005) [148] found an association between increased white matter
density in left precentral gyrus and longer duration of cannabis
use.
1.2. Diffusion tensor imaging (DTI) studies. Four studies
have used DTI to examine the integrity of white matter tracts in
chronic cannabis users [144,147,150,151], of which half have
reported positive results [144,147]. Arnone et al. (2008) [144]
found increased mean diffusivity (MD) in the corpus callosum
while Gruber et al. (2011) [147] found increased MD in the right
genu as well as reductions in left frontal fractional anisotropy (FA).
Gruber et al. (2011) [147] also reported a positive association
between left frontal FA and impulsivity scores, and higher FA and
lower MD in the frontal lobes being associated with a later age of
initiation of cannabis use.
2. Structural neuroimaging studies in adolescent chronic
cannabis users
Three volumetric studies in adolescent chronic cannabis users
were included, two of which consist of the same sample [154,155].
As an exception, these two studies [154,155] were included despite
involving participants with symptoms of alcohol dependence given
the modest number of studies included in this population (for
details see Table 1). The MRI scans, focused on specific regions of
interest and were obtained following 28 days of abstinence from
cannabis use. Medina et al. (2009, 2010) [154,155] reported
significantly larger volumes of the inferior posterior vermis, as well
as a marginal group-by-gender interaction in the prefrontal cortex,
in which female and male cannabis users demonstrated, respec-
tively, larger and smaller prefrontal cortex volumes compared to
the same-gender controls. McQueeny et al. (2011) [156] also
described an effect of gender in which female cannabis users but
not males, exhibited a larger right amygdala volume.
In terms of correlations, Medina et al. (2010) [155] found that
larger volumes of the vermis were associated with poorer executive
functioning while McQueeny et al. (2011) [156] found that larger
right amygdala volume was associated with more internalizing
symptoms (e.g., anxiety/depression). Lastly, Medina et al. (2009)
[154] also found that increased volume in the prefrontal cortex
was associated with poorer executive functioning among cannabis
users while the opposite pattern was observed in controls,
suggesting that female users may be at increased risk for
cannabis-induced prefrontal abnormalities.
3. Functional neuroimaging studies in adult chronic
cannabis users
3.1. Resting state. We included eight case-control studies
comparing resting rCBF in adult chronic cannabis users and non
cannabis using healthy controls (Table 2). The imaging methods
used were as follows: H215O-PET [157], 133Xe-SPECT [158],
18F-FDG-PET [159], [11C]- raclopride-PET [159–162] and
[18F]FMPEP-d2 [163]. Functional differences between groups
were found in all studies, except for the four [11C]-raclopride-PET
studies [159–162]. Abstinence periods ranged from 12 hours to
542 days (for details see Table 2). Block et al. (2000) [157]
described reduced bilateral rCBF in the posterior cerebellum and
ventral prefrontal cortex but also increased rCBF in the anterior
cingulate cortex in cannabis users. Lundqvist et al. (2001) [158]
found a trend of lower global CBF in cannabis users, as well as
reduced rCBF in the right prefrontal and superior frontal cortex.
Sevy et al. (2008) [159] reported lower glucose metabolism in the
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right orbitofrontal cortex, putamen bilaterally and precuneus in
chronic cannabis users. However, there were no significant
differences between the groups in striatal D2/D3 receptor
availability and no correlation between striatal [11C]-raclopride-
PET binding potential and glucose metabolism [159]. Consistent
with these results, three other [11C]- raclopride-PET studies [160–
162] failed to find any differences between groups in dopamine
D2/D3 receptor availability in the striatum as a whole or it
functional subdivisions. However, while Stokes et al. (2012) [160]
also failed to find any association between lifetime frequency of
cannabis use and binding potential values, Albrecht et al. (2012)
[161] described a negative correlation with both urine levels of
cannabis metabolites and self-report of recent cannabis consump-
tion. Finally, Hirvonen et al. (2011) [163] demonstrated a
reversible and regionally selective downregulation of CB1
receptors. At baseline, current users had approximately 20% less
CB1 receptor density in the neocortex and limbic regions, which
was negatively correlated with years of cannabis exposure. After
four weeks of abstinence from cannabis use, CB1 receptor density
returned to normal levels in all brain regions, except for the
hippocampus [163].
3.2. Cognitive paradigms. We identified 16 studies in adult
chronic cannabis users that compared regional activation during
the performance of a cognitive task with healthy controls (Table 2),
four with PET [164–167] and twelve with fMRI [151,152,168–
177].
Attention
Chang et al. (2006) [169] used fMRI to compare a visual-
attention task in current and abstinent cannabis users with healthy
controls. Despite all groups showing normal task performance,
both active and abstinent chronic cannabis users demonstrated
decreased activation in the right prefrontal, medial and dorsal
parietal cortices and medial cerebellar regions but greater
activation in several smaller regions throughout the frontal,
posterior parietal, occipital and cerebellum. An apparent normal-
ization of BOLD signal was described in the right prefrontal and
medial cerebellar regions in those with a longer duration of
abstinence. In addition, early age of onset and estimated
cumulative cannabis lifetime exposure were both associated with
reduced activation in the right prefrontal cortex and medial
cerebellum. More recently, Abdullaev et al. (2010) [168] used two
attention tasks [the use generation task and the attention network
task (ANT)] to contrast differences between cannabis users and
healthy controls. Chronic cannabis users showed poorer perfor-
mance in the ANT (more errors and longer reaction time), as well
as stronger activation within the right prefrontal cortex in both
tasks and within the parietal cortices in the ANT, which may
indicate a less efficient system for the executive control of attention
during conflict resolution tasks. Finally, Harding et al. (2012) [171]
demonstrated for the first time that long-term heavy cannabis use
is associated with increased functional connectivity between
several frontal cortex regions and the occipitoparietal cortex using
the Multi-Source Interference Task (MSIT). No differences in
behavioural performance were evident between groups. The
authors suggest that their findings may suggest a compensatory
role for these regions in mitigating the effects of abnormal
attentional and visual processing following chronic cannabis
exposure [171].
Memory
In a H215O-PET study, Block et al. (2002) [164] found that
cannabis users performed verbal memory tasks more poorly than
controls. This was associated with reduced activation in the
prefrontal cortex and greater activation in the posterior cerebel-
lum, as well as with an absence of lateralization of hippocampal
activity. Consistent with this, Jager et al. (2007) [152] described
attenuated activity in the right dorsolateral prefrontal cortex and
bilateral (para) hippocampal gyri in cannabis users despite normal
performance in an associative memory task. Finally, in a verbal
working memory task, Jager et al. (2006) [173] found significantly
greater activity in the left superior parietal cortex in the cannabis
using group despite there being no differences in task performance,
which may be consistent with the idea of a compensatory
recruitment effect.
Inhibition and impulsivity
Eldreth et al. (2004) [166] and Gruber et al. (2005) [151] studied
the degree of inhibitory control during a Stroop task in current
(positive THC urine analysis) and abstinent chronic cannabis
users, respectively. Gruber et al. (2005) [151] found lower anterior
cingulate activity and higher mid-cingulate and bilateral dorsolat-
eral prefrontal cortex activity in current cannabis users relative to
healthy controls, who demonstrated focal increased activity within
the right dorsolateral prefrontal cortex. Consistently, Eldreth et al.
(2004) [166] found in abstinent cannabis users a reduced anterior
cingulate activation using H215O-PET during the performance of
a modified Stroop test. However, they also reported a reduced
dorsolateral prefrontal cortex activation and a greater activation in
the hippocampus bilaterally [166]. Lastly, Hester et al. (2009) [172]
administered a go/no-go response inhibition task to active
cannabis users to determine inhibitory control and error awareness
compared with healthy controls. Although control performance
was equivalent between the two groups, cannabis users displayed a
significant deficit in awareness of commission errors, which was
associated with decreased a activity in the anterior cingulate cortex
and right insula, as well as in the bilateral inferior parietal and
middle frontal regions [172].
Decision-making
Bolla et al. (2005) [165] and Vaidya et al. (2011) [167] using
H215O-PET, and Wesley et al. (2011) [177] using fMRI, studied
the brain activation pattern in chronic cannabis users compared to
healthy controls during the Iowa Gambling Task (IGT). Bolla et al.
(2005) [165] reported dysfunction during the performance of the
task in abstinent cannabis users, demonstrating a lower activation
in the right orbitofrontal cortex and dorsolateral prefrontal cortex
and greater activation in the left parietal and cerebellar cortices.
The number of joints used per week was positively correlated with
activation in the right parahippocampal gyrus but inversely
correlated with activation in the right cerebellum and orbital
gyrus. Wesley et al. (2011) [177] also reported a poorer
performance on the IGT in active cannabis users. However, there
were no differences during the initial strategy development phase,
in which cannabis users showed reduced activity in response to
losses in anterior cingulate cortex, ventromedial prefrontal cortex,
precuneus, superior parietal lobe, occipital lobe and cerebellum
compared to controls [177]. Additionally, the functional response
to losses in anterior cingulate, ventromedial and rostral prefrontal
cortices was positively correlated with improvement over the task
course only in the control group, indicating that cannabis users
may be less sensitive to negative feedback during the strategy
development phase [177]. In contrast, Vaidya et al. (2011) [167]
did not find differences on the standard IGT performance between
active cannabis users and healthy controls. Nevertheless, cannabis
users performed significantly worse than controls on a variant
version of the same task [178]. Both groups showed increased
activity in ventromedial prefrontal cortex on both versions of the
Neuroimaging Studies in Chronic Cannabis Users
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IGT compared to the control task but in contrast to Wesley et al.
(2011) [177], cannabis users demonstrated greater activity than
controls in the ventromedial prefrontal cortex on the standard
IGT, as well as in the cerebellum and the anterior insula on both
versions of the IGT [167]. Furthermore, duration of cannabis use
was associated with greater activity in ventromedial prefrontal
cortex [167]. Nestor et al. (2010) [175] and van Hell et al. (2010)
[176] used fMRI to measure brain activity during reward and
anticipation of loss with different versions of a monetary reward
task. There were no significant behavioural differences between
the groups in both studies. Nestor et al. (2010) [175] reported a
greater right ventral striatum activity in cannabis users during
reward anticipation, which was significantly correlated with years
of lifetime cannabis use. In addition, response to loss and loss
avoidance outcome notification was related with hypoactivity in
left insula, and in the post hoc analysis comparing loss and win
cues with no-outcome cues, right ventral putamen showed greater
BOLD response [175]. Conversely, comparing cannabis users to
non tobacco-smoking controls, van Hell et al. (2010) [176]
demonstrated attenuated activity in the nucleus accumbens and
caudate nucleus bilaterally during reward anticipation, as well as
left putamen and right inferior and medial frontal gyrus, superior
frontal gyrus bilaterally and left cingulate gyrus. Cannabis users
showed enhanced reward anticipation activity in the middle
temporal gyrus bilaterally, right cuneus and right parahippocam-
pal gyrus. When compared to tobacco-smoking controls, cannabis
users also showed reduced anticipation activity in the same areas,
with the exception of the nucleus accumbens bilaterally, the right
medial frontal gyrus and the left cingulated gyrus, indicating that
anticipation activity in these regions may be attenuated by both
cannabis and nicotine [176]. In accordance with Nestor et al.
(2010) [175], response to contrasted outcome notification was
associated with greater activity in the putamen bilaterally and the
right caudate nucleus compared with non-smoking controls [176].
The putamen was more activated in cannabis users than in non-
smokers and tobacco-smoking controls, indicating that changes in
this area were mainly due to cannabis use [176].
Motor performance
King et al. (2011) [174] reported that chronic cannabis use was
associated with slower and less efficient psychomotor function,
especially in male users. Cannabis users showed lesser activation in
the lingual gyrus and greater activation of the superior frontal
gyrus compared to controls while performing a visually paced
finger sequencing task, suggesting that the former group shifted
from more automated visually-guided responses to more executive
or attention control regions of the brain [174].
Affective processing
Gruber et al. (2009) [170] examined the BOLD signal changes
for two target affective conditions (happy and anger). Region of
interest analyses revealed that cannabis users demonstrated
relatively lower anterior cingulate and amygdalar activity during
the presentation of masked angry stimuli sets relative to the control
group, who showed relatively higher activation within these
regions. In contrast, cannabis users demonstrated a larger pattern
of activation during the presentation of masked happy faces within
the cingulate as compared to controls, with no increase in
amygdalar activation [170]. Furthermore, the total number of
smoking episodes per week was positively associated with cingulate
activity during the viewing of masked angry faces and positively
associated with amygdalar activity during the viewing of masked
happy faces [170]. Finally, overall cannabinoid level was positively
related to cingulate activity during the viewing of masked happy
faces [170]. The disparate activation patterns showed between
groups suggest a different way of processing emotional information
between groups [170].
4. Functional neuroimaging studies in adolescent chronic
cannabis
We included five case-control fMRI studies in adolescent
cannabis users comparing brain activity with healthy controls
during a cognitive task performance. As an exception, two of them
[180,181] were included despite involving a minor proportion of
participants with a co-morbid alcohol dependence given the
relatively modest number of studies in this population (for details
see Table 2). No resting state studies were identified in the
adolescent population.
Memory
Padula et al. (2007) [179] and Schweinsburg et al. (2008, 2010)
[180,181] examined fMRI response during a spatial working
memory (SWM) task. In a group of abstinent adolescent cannabis
users, Padula et al. (2007) [179] described increased activity in the
left temporal gyrus and anterior cingulate cortex but lower activity
in right temporal gyrus, thalamus, pulvinar and left parahippo-
campal gyrus related to higher scores on the task, while the reverse
pattern was found in the controls. This may suggest that cannabis
users employed more of a verbal strategy to achieve the same level
of task performance as the controls [179]. Additionally, cannabis
users demonstrated greater performance-related activation in the
right basal ganglia, precuneus, postcentral gyrus and bilateral
superior parietal lobe [179], again suggesting a compensatory
neural effort. Consistent with this, Schweinsburg et al. (2008) [180]
also found a different pattern of activation in abstinent adolescent
cannabis users who performed the SWM task similarly to the
control group. Thus, cannabis users demonstrated higher activa-
tion in the right parietal cortex but also lower activity in the right
dorsolateral prefrontal and occipital cortices [180]. Finally, in a
cross-sectional study, Schweinsburg et al. (2010) [181] compared
fMRI responses using the same task among adolescent cannabis
users with brief and sustained cannabis abstinence and healthy
controls. Although both groups performed at a similar level on the
task, recent users showed greater activity in the medial and left
superior prefrontal cortices and bilateral insula while abstinent
users demonstrated an increased response in the right precentral
gyrus [181]. More recently, Schweinsburg et al. (2011) [182]
compared fMRI response during a verbal paired associates
encoding task in 3 groups of participants that included an
abstinent cannabis user group, a binge drinker group and a
cannabis user group with co-morbid binge-drinking to healthy
controls with very limited alcohol or cannabis experience. In
general, each group displayed deviations in BOLD response
relative to non-using controls, and binge drinking and cannabis
use demonstrated independent as well as interactive effects on
brain functioning [182].
Inhibition and impulsivity
In a group of abstinent cannabis users, Tapert et al. (2007) [183]
compared the activation pattern on a go/no-go task during fMRI
with seventeen healthy subjects. Despite similar level of task
performance, cannabis users showed greater activation during
inhibitory trials in the right dorsolateral prefrontal, bilateral
medial frontal, bilateral inferior and superior parietal lobules and
right occipital gyrus compared to the healthy subjects. During the
non-inhibitory trials, differences were located in right prefrontal,
insular and parietal cortices, with cannabis users showing greater
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activation in these areas compared to the controls. As observed in
adults, these results suggest a greater neurocognitive effort during
the task in cannabis users, even after the abstinence period.
Discussion
In this systematic review, we identified 43 studies suitable for
inclusion regarding the impact of chronic cannabis use on brain
structure and functioning, of which eight (19%) were in the
adolescent population. Despite the high degree of heterogeneity
among the studies reviewed herein, several relatively consistent
findings emerged from this review. These findings, discussed in
detail below, include: (1) Structural brain abnormalities, mainly in
CB1-rich areas implicated in several cognitive functions, which
may be related to the amount of cannabis use; (2) Altered neural
activity during resting state and under several different types of
cognitive paradigms, that may reflect a different recruitment of
brain areas during the tasks, particularly within the prefrontal
cortex; and (3) The few studies conducted in adolescents suggest
that both structural and functional alterations may appear soon
after starting the drug use and may be related to gender.
In terms of structural findings, specific regional brain analyses
demonstrated evidence of structural abnormalities when adult
chronic cannabis users were compared with healthy controls. The
most consistently reported brain alteration was reduced hippo-
campal volume [145,146,148,149], which was shown to persist
even after several months of abstinence in one study [145] and also
to be related to the amount of cannabis use [145,146,149]. Other
frequently reported morphological brain alterations related to
chronic cannabis use were reported in the amygdala
[146,149,156], the cerebellum [146,155] and the frontal cortex
[148,154]. Lastly, two DTI studies found differences in the mean
diffusivity or fractional anisotropy in the corpus callosum and the
frontal white matter fibre tract [144,147], suggesting that chronic
cannabis exposure may also alter white matter structural integrity,
by either affecting demyelination or causing axonal damage or
indirectly through delaying normal brain development. With
regard to the few structural MRI studies focusing on the effects of
cannabis use on brain morphology in adolescents, some discrep-
ancies were reported related to adult population. These inconsis-
tencies may be explained in terms of the disruption of normal
pruning during developmental maturation due to early chronic
cannabis use, ultimately resulting in larger regional volumes [156].
Notwithstanding, structural results from adolescent population
suggest that the effects of chronic cannabis use may appear soon
after starting the drug use, persist after a month of abstinence or
even be moderated by gender [145,154–156]. In this context, it
has been reported that adolescent female cannabis users may be at
increased risk for cannabis-induced morphological effects
[154,156].
Functional neuroimaging studies that have evaluated the resting
state in active and abstinent adult chronic cannabis users suggest
that resting global [158], prefrontal cortical [157–159], cerebellar
[157] and striatal [159] blood flow may be lower compared with
controls. These brain regions correspond to areas with relatively
high concentration of CB1 receptors [19]. Hence, it has been
hypothesised that the decreased resting state function may
represent a down-regulation of CB1 receptors as a result of
regular exposure to cannabis [41]. However, it is important to
note that not all studies have consistently demonstrated effects in
these regions. Furthermore, it has been recently found that, similar
to animal studies, down-regulation of CB1 receptors in humans is
region-specific and reversible, occurring in the neocortex and
limbic cortex but neither in subcortical brain regions nor in the
cerebellum [163]. It is also noteworthy that these brain regions
correspond to areas that are engaged in the processing of reward
[184]. This is also consistent with the evidence of neuropsycho-
logical impairments in chronic cannabis users, such as in attention
and working memory [185], decision making [186], and
psychomotor speed [187]. Also, consistent with experimental
animal studies, no differences in striatal D2/D3 receptor
availability were found in four studies of chronic cannabis users
compared with healthy controls [159–162]. However, in the only
study where the chronic cannabis users were not abstinent [161],
an inverse correlation between recent cannabis consumption and
D2/D3 receptor availability was found, leading the authors to
suggest that this effect could be related to a direct effect of
cannabis smoking on the expression of striatal DA receptors in
heavy cannabis users [161]. Additional studies are needed to better
understand the neurochemical basis of this finding.
Functional imaging studies comparing activation in both adult
and adolescent chronic cannabis users with healthy controls
during the performance of different cognitive tasks indicated that
chronic cannabis users would use similar brain areas that engage
these cognitive processes but often demonstrating an altered
pattern of brain activity [151,152,157,165–177,179,181–183].
However, the level of performance of the cannabis users on the
cognitive tasks employed was generally similar to that of controls
[164,165,168,171,174,177], or at least within what may be
considered a normal range of test performance. Therefore, these
findings may be interpreted as reflecting neuroadaptation, perhaps
indicating the recruitment of additional regions as a compensatory
mechanism to maintain normal cognitive performance in response
to chronic cannabis exposure [151,152,164,166,171,172,175,179–
181,183], particularly within the prefrontal cortex area
[151,166,168,169,171,181,183]. In this regard, the brain seems
able to achieve some degree of reorganization, activating brain
regions not usually needed to perform the cognitive task in
response to an impaired ability of the normally engaged task
network. Thus, it is feasible that drug-related compensatory
mechanism may work for a period of time until it turns out to be
insufficient and differences between groups become apparent.
However, the impact of these subtle brain alterations on social,
familiar and occupational life as well as its potential relationship
with psychiatric disorders remains speculative.
A further important issue emerging out of this review is that few
studies have investigated the effects of chronic cannabis use on the
brain in adolescence subjects. In light of the popularity of cannabis
among teenagers [1,2] and recent data showing the potential
neurotoxic effects of chronic cannabis use on the maturational
brain [188], investigation of the possible long-term effects on brain
structure and function in the adolescent population should be a
priority both from the scientific and population health perspective
[34,188]. Future studies should consider the need for convergent
methodology, replication of known facts with greater methodo-
logical rigor, and prospective large samples involving subjects of
both genders across the life-span from adolescence to adulthood to
delineate the evolution and reversibility of previously reported
alterations.
Limitations of the review
Results presented here have pointed out some important
methodological differences that limit the generalisation of results
and comparison between studies and have doubtless contributed to
the slightly disparate array of findings. Despite the use of a strict
definition of chronic cannabis user and robust application of
inclusion and exclusion criteria in an attempt to avoid excessive
heterogeneity between samples, studies often diverged on certain
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socio-demographic characteristics and cannabis use parameters,
such as gender-bias, age of onset, lifetime use and abstinence period
before the acquisition of imaging data. Moreover, it is well known
that the THC content of smoked cannabis varies markedly between
sources and preparations, with potency reported to have increased
substantially over the past ten years [2]. Thus, comparability of
earlier to later studies may not always be appropriate [44].
Furthermore, the exclusion of studies involving recreational and
naı̈ve cannabis users implies that the question of whether the brains
of these subjects are adversely affected by cannabis is not addressed
within the framework of the present review. Another important
confounding factor is the inclusion of subjects with concurrent use of
tobacco, which may affect neural activity as well as potentially
interact with the effects of cannabis use [176]. In addition, it is
known that co-morbid misuse of alcohol and other illicit drugs, such
as cocaine and methamphetamine, may also be associated with
significant neurobiological, neurocognitive and psychiatric abnor-
malities [189]. In the present review, although we excluded studies
involving subjects with alcohol dependence, some included subjects
with alcohol misuse (abuse [145,179] or excessive consumption
[150]), or reported differences in alcohol intake parameters
to]despite alcohol consumption was within safe limits
[143,144,147,156,157,163,164,169,170]. Moreover, given the rel-
atively modest number of studies in the adolescent population, we
included four studies which may involve some participants with co-
morbid alcohol dependence [154,155,180,181]. In all these studies,
the interaction of alcohol with cannabis use, as well as its
contribution to the brain effects cannot be ruled out. On the other
hand, the exclusion of those with alcohol dependence, often highly
co-morbid with cannabis use, may restrict the generalization of the
results to the majority of chronic cannabis users [190].
With regard to other methodological limitations, some studies
have reported modest sample sizes, sometimes below the threshold
that would be currently regarded as acceptable (for instance, for
PET or SPECT studies 10 subjects and for fMRI studies 15
subjects) [29]. In this regard, strategies for expanding data-sharing
would be a welcome development in future research (i.e. The
Function Biomedical Informatics Research Network [191] or the
1000 Functional Connectomes project [192,193]). However,
further obstacles must be addressed to make collaborative analysis
efficient, such as between-site differences in scanners and data
acquisition parameters, as well as pre- and post-processing
schemes. The cross-sectional designs of most of the studies
reviewed here complicated the interpretation of results as pre-
existing morphological or functional alterations cannot be ruled
out. Furthermore, studies that merely compare those subjects
exposed to an environmental factor from those that are not, are
likely to promote interpretation biases whereby study findings,
irrespective of their direction, tend to be interpreted as detrimen-
tal. Longitudinal evaluations in larger samples may thus prove
particularly useful. With regard to technical limitations, it is
remarkable to note that the resting state studies did not control for
spontaneous neutral activity and modulation of the BOLD signal,
and the functional studies often reported different imaging
methods and explored different brain functions using diverse
cognitive paradigms, hampering the comparison between the
studies. Hence, replication of previous results is critically
important. Convergent methodology to sort out the current
inconsistencies and controversies among studies would be impor-
tant for future research in the field.
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